MaxCyte, Inc.

As of June 30, 2026, MaxCyte, Inc. carries a market capitalization of 113.56M, placing it among publicly traded companies globally. Its enterprise value stands at 36.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MaxCyte, Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, MaxCyte, Inc. has 106.13M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.20, and the price-to-book ratio stands at 0.82.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 36.15M versus a market cap of 113.56M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, MaxCyte, Inc. maintains a current ratio of 12.26, meaning it holds 12.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, MaxCyte, Inc. posted a negative return on equity (ROE) of -20.39, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -17.62, reflecting losses generated across the asset base. The company generates approximately 280,919.28 in revenue per employee across its workforce of 96.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.82 indicates how many times MaxCyte, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, MaxCyte, Inc.'s stock has declined approximately 7.75% over the past 52 weeks. The 50-day moving average sits at 1.07, while the 200-day moving average is 0.92.

Over the twelve months ended June 30, 2026, MaxCyte, Inc. generated 27.18M in revenue and converted that into -31.19M in net income, yielding earnings per share of -0.29. EBITDA reached -32.17M, while operating income came in at -30.79M.

As of June 30, 2026, MaxCyte, Inc. holds 92.51M in cash and equivalents against 15.10M in total debt, resulting in a net debt position of -13.17M. Total book value stands at 138.96M, with working capital of 97.49M providing operational flexibility.

MaxCyte, Inc. produced -20.11M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -713,369.50 in capital expenditures, free cash flow totaled -20.83M - equivalent to -0.20 per share.

Over the twelve months ended June 30, 2026, MaxCyte, Inc. posted a gross margin of 79.23, reflecting its pricing power and cost economics. The operating margin of -113.30 and net profit margin of -114.77 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -18.23: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.00, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to MaxCyte, Inc. shareholders.

As of June 30, 2026, MaxCyte, Inc. has an Altman Z-Score of 1.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.